secwatch.observer — SEC 8-K summary
======================================

Issuer:     MeiraGTx Holdings plc (MGTX)
CIK:        0001735438
Form:       8-K
Filed at:   2021-12-07T23:59:59+00:00
Accession:  0001558370-21-016575
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MeiraGTx reports positive Phase 1 data for AAV-hAQP1 in radiation-induced xerostomia; 6/7 patients improved
--------------------------------------------------------------------------------

- 6 of 7 participants achieved clinically meaningful improvement in xerostomia symptoms on two validated PRO measures.
- One participant maintained maximal symptom improvement score of 7 at 24 months post-treatment.
- AAV-hAQP1 well tolerated with no dose-limiting toxicities or serious adverse events reported.
- Company plans to initiate a randomized, double-blind, placebo-controlled Phase 2 study in H2 2022.
- Target market: ~170,000 US patients with grade 2/3 RIX; no new treatments approved in >20 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1735438/000155837021016575/0001558370-21-016575-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1735438/000155837021016575/mgtx-20211207x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-21-016575

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer